Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden
Viktor Molander, Hannah Bower, Thomas Frisell, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 2, pp. 169-175
Open Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Peter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 1, pp. 71-87
Open Access | Times Cited: 235
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study
Roy Fleischmann, Eduardo Mysler, Louis Bessette, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002012-e002012
Open Access | Times Cited: 83
Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases
Claudia A. Salinas, Anthony Louder, Jennifer M. Polinski, et al.
Rheumatology and Therapy (2022)
Open Access | Times Cited: 81
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
Lars Erik Kristensen, Silvio Danese, Arne Yndestad, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 7, pp. 901-910
Open Access | Times Cited: 79
Waiting for JAK inhibitor safety data
Tue Wenzel Kragstrup, Bente Glintborg, Anne-Marie Svensson, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002236-e002236
Open Access | Times Cited: 73
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis
Viktor Molander, Hannah Bower, Thomas Frisell, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 189-197
Open Access | Times Cited: 65
The potential role of ischaemia–reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications
Douglas B. Kell, Etheresia Pretorius
Biochemical Journal (2022) Vol. 479, Iss. 16, pp. 1653-1708
Open Access | Times Cited: 52
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
Roy Fleischmann, Jeffrey R. Curtis, Christina Charles‐Schoeman, et al.
Annals of the Rheumatic Diseases (2023), pp. ard-223916
Open Access | Times Cited: 34
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors
Victor Yang, Tue Wenzel Kragstrup, Christopher McMaster, et al.
Drug Safety (2023) Vol. 46, Iss. 11, pp. 1049-1071
Open Access | Times Cited: 28
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Peter C. Taylor, Thomas Bieber, Rieke Alten, et al.
Advances in Therapy (2023) Vol. 40, Iss. 4, pp. 1867-1883
Open Access | Times Cited: 26
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
Peter C. Taylor, Cedric Laedermann, Rieke Alten, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4527-4527
Open Access | Times Cited: 23
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study
Maya H Buch, Deepak L. Bhatt, Christina Charles‐Schoeman, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003912-e003912
Open Access | Times Cited: 9
Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
Robert Harrington, Patricia Harkins, Richard Conway
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6690-6690
Open Access | Times Cited: 21
Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis
J Zhang, Wenhui Li, Mingli Gong, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 17
Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review
Shunsuke Mori, Fumihiko Ogata, Ryusuke Tsunoda
Clinical Rheumatology (2021) Vol. 40, Iss. 11, pp. 4457-4471
Open Access | Times Cited: 34
Recommendations from the ICM-VTE: General

Journal of Bone and Joint Surgery (2022) Vol. 104, Iss. Suppl 1, pp. 4-162
Open Access | Times Cited: 25
A Narrowing Mortality Gap: Temporal Trends of Cause‐Specific Mortality in a National Matched Cohort Study in US Veterans With Rheumatoid Arthritis
Tate Johnson, Yangyuna Yang, Punyasha Roul, et al.
Arthritis Care & Research (2022) Vol. 75, Iss. 8, pp. 1648-1658
Open Access | Times Cited: 25
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
Jeffrey I. Weitz, Zoltán Szekanecz, Christina Charles‐Schoeman, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002571-e002571
Open Access | Times Cited: 23
Recommendations for assessing the risk of cardiovascular disease and venous thromboembolism before the initiation of targeted therapies for chronic inflammatory rheumatic diseases
Jérôme Avouac, O. Fogel, Sophie Hecquet, et al.
Joint Bone Spine (2023) Vol. 90, Iss. 5, pp. 105592-105592
Open Access | Times Cited: 16
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients
Christina Charles‐Schoeman, Roy Fleischmann, Eduardo Mysler, et al.
Arthritis & Rheumatology (2024) Vol. 76, Iss. 8, pp. 1218-1229
Open Access | Times Cited: 6
Risk of cardiovascular comorbidities before and after the onset of rheumatic diseases
Hanna-Kaisa Aaramaa, Nina Mars, Mika Helminen, et al.
Seminars in Arthritis and Rheumatism (2024) Vol. 65, pp. 152382-152382
Open Access | Times Cited: 5
JAK-Inhibitors – A Story of Success and Adverse Events
Rebekka Wlassits, Mathias Müller, Karl Heinrich Fenzl, et al.
Open Access Rheumatology Research and Reviews (2024) Vol. Volume 16, pp. 43-53
Open Access | Times Cited: 5
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance
George Karpouzas, Zoltán Szekanecz, Eva Baecklund, et al.
Therapeutic Advances in Musculoskeletal Disease (2023) Vol. 15
Open Access | Times Cited: 13
Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis
Styliani Partalidou, Dimitrios Patoulias, Kleopatra Deuteraiou, et al.
Mediterranean Journal of Rheumatology (2024) Vol. 35, Iss. Suppl 1, pp. 10-10
Open Access | Times Cited: 4
Practical Implementation of Artificial Intelligence-Based Deep Learning and Cloud Computing on the Application of Traditional Medicine and Western Medicine in the Diagnosis and Treatment of Rheumatoid Arthritis
Shaohui Wang, Ya Hou, Xuanhao Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top